Icad Inc (ICAD) 10.31 $ICAD
iCAD to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call on Tuesday, February 24, 2015
GlobeNewswire - Fri Feb 13, 7:30AM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2014 after market close on Tuesday, February 24, 2015.
ICAD: 10.31 (-0.08)
15.2% Return Seen to Date on SmarTrend Icad Call (ICAD)
Comtex SmarTrend(R) - Fri Jan 30, 9:32AM CST
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on December 11th, 2014 at $9.37. In approximately 2 months, Icad has returned 15.15% as of today's recent price of $7.95.
ICAD: 10.31 (-0.08)
iCAD Announces More Than 500 Patients Treated In Study Of Intraoperative Radiation Therapy (IORT) For Early-Stage Breast Cancer
PR Newswire - Wed Dec 10, 4:02PM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced today that more than 500 patients have been treated in its clinical trial of intraoperative radiation therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®. The study, "A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent eBx System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer (the ExBRT study)," compares the Xoft System to traditional external beam radiation therapy (EBRT). Patients in the study were treated with a targeted, single-fraction dose of radiation using the Xoft System at the time of lumpectomy.
ICAD: 10.31 (-0.08)
iCAD to Present at LD MICRO "Main Event" Micro-Cap Growth Conference on Tuesday, December 2, 2014
Business Wire - Wed Nov 26, 7:00AM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Company management will participate in the upcoming LD MICRO "Main Event" Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Ken Ferry, President and CEO of iCAD, Inc., will present a corporate overview on Tuesday, December 2, 2014 at 12:30 p.m. PST (3:30 p.m. EST).
ICAD: 10.31 (-0.08)
iCAD Showcases Advanced Mammography and Computed Tomography Colonography (CTC) CAD Solutions at Radiological Society of North America 2014 Annual Meeting
PR Newswire - Tue Nov 25, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will feature advanced computer-aided detection (CAD) solutions for the early detection of breast and colon cancers during the 100th Annual Meeting of the Radiological Society of North America (RSNA), in Chicago, Nov. 30 - Dec. 5. Symposia, posters, and workshops discuss the application of iCAD technologies and workflow solutions for enhanced cancer identification, breast density analysis, and tumor characterization. iCAD's 2D mammography, tomosynthesis, and Computed Tomography Colonography (CTC) CAD and workflow technologies will be featured at booth #4135 in Hall A.
ICAD: 10.31 (-0.08)
iCAD raises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:46AM CDT
ICAD: 10.31 (-0.08)
iCAD (ICAD) CEO Ken Ferry on Q3 2014 Results - Earnings Calls Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 9:45PM CDT
ICAD: 10.31 (-0.08)
iCAD, Inc. beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:21PM CDT
ICAD: 10.31 (-0.08)
iCAD Reports Third Quarter Financial Results
Business Wire - Tue Oct 28, 3:06PM CDT
--Increases Financial Guidance for 2014
ICAD: 10.31 (-0.08)
iCAD to Host Third Quarter 2014 Financial Results Conference Call on Tuesday, October 28, 2014
PR Newswire - Tue Oct 21, 7:30AM CDT
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the three and nine months ended September 30, 2014 following the close of the market on Tuesday, October 28, 2014.
ICAD: 10.31 (-0.08)
Icad Shares Up 36.0% Since SmarTrend's Buy Recommendation (ICAD)
Comtex SmarTrend(R) - Thu Sep 25, 9:11AM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 2 months, Icad has returned 35.98% as of today's recent price of $9.94.
ICAD: 10.31 (-0.08)
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into iCAD Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Thu Sep 18, 4:15PM CDT
Levi & Korsinsky, LLP is investigating iCAD Inc. (Nasdaq: ICAD) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
ICAD: 10.31 (-0.08)
Icad Has Returned 37.8% Since SmarTrend Recommendation (ICAD)
Comtex SmarTrend(R) - Wed Sep 17, 4:40PM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 2 months, Icad has returned 37.76% as of today's recent price of $10.07.
ICAD: 10.31 (-0.08)
iCAD to Present at the 5th Annual Craig-Hallum Alpha Select Conference
Business Wire - Wed Sep 17, 7:30AM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announces that Company management will participate in the 5th Annual Craig-Hallum Alpha Select Conference taking place on Thursday, September 18th at the Convene Conference Center in New York City. Ken Ferry, President and Chief Executive Officer of iCAD, will be presenting a corporate overview at 1:30 pm in the Murray Hill Room.
ICAD: 10.31 (-0.08)
iCAD to Showcase its Comprehensive Electronic Brachytherapy Solutions and Services at 56th Annual American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting
PR Newswire - Thu Sep 11, 7:00AM CDT
(Booth #1938) -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will debut the Company's latest technological advances and present updates on clinical data and patient outcomes using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® in the treatment of cancer during the upcoming American Society for Therapeutic Radiology and Oncology (ASTRO) meeting taking place September 14-17, 2014 at the Moscone Center in San Francisco. Throughout the meeting, iCAD will also showcase its expanded and comprehensive software and service offerings following the recent acquisitions of DermEbx and Radion, and will highlight innovations in technology with live product demonstrations of its Xoft System at Booth #1938.
ICAD: 10.31 (-0.08)
Icad Up 50.2% Since SmarTrend Uptrend Call (ICAD)
Comtex SmarTrend(R) - Wed Sep 10, 10:58AM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 2 months, Icad has returned 50.22% as of today's recent price of $10.98.
ICAD: 10.31 (-0.08)
iCAD Expands Partnership with Volpara Solutions to Offer Enhanced Breast Imaging Analytics for 2D Mammography and Tomosynthesis
PR Newswire - Thu Sep 04, 7:00AM CDT
iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that, in addition to Volpara®Density(TM) volumetric breast density assessment software, Volpara®Analytics(TM) and Volpara®Dose(TM) solutions are now available as part of iCAD's PowerLook Advanced Mammography Platform (AMP)®. With the addition of these quantitative breast imaging tools, radiologists will be able to evaluate the performance of all major digital mammography and tomosynthesis units and obtain patient-specific dose information to make informed treatment decisions in real time.
ICAD: 10.31 (-0.08)
Icad Has Returned 50.2% Since SmarTrend Recommendation (ICAD)
Comtex SmarTrend(R) - Wed Sep 03, 9:35AM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 2 months, Icad has returned 50.18% as of today's recent price of $10.98.
ICAD: 10.31 (-0.08)
Uptrend Call Working As Icad Stock Rises 42.7% (ICAD)
Comtex SmarTrend(R) - Wed Aug 27, 9:13AM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 1 month, Icad has returned 42.68% as of today's recent price of $10.43.
ICAD: 10.31 (-0.08)
Shares of ICAD Up 38.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 19, 4:48PM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 1 month, Icad has returned 38.29% as of today's recent price of $10.11.
ICAD: 10.31 (-0.08)
iCAD to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call on Tuesday, February 24, 2015
GlobeNewswire - Fri Feb 13, 7:30AM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2014 after market close on Tuesday, February 24, 2015.
ICAD: 10.31 (-0.08)
15.2% Return Seen to Date on SmarTrend Icad Call (ICAD)
Comtex SmarTrend(R) - Fri Jan 30, 9:32AM CST
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on December 11th, 2014 at $9.37. In approximately 2 months, Icad has returned 15.15% as of today's recent price of $7.95.
ICAD: 10.31 (-0.08)
iCAD Announces More Than 500 Patients Treated In Study Of Intraoperative Radiation Therapy (IORT) For Early-Stage Breast Cancer
PR Newswire - Wed Dec 10, 4:02PM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced today that more than 500 patients have been treated in its clinical trial of intraoperative radiation therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®. The study, "A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent eBx System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer (the ExBRT study)," compares the Xoft System to traditional external beam radiation therapy (EBRT). Patients in the study were treated with a targeted, single-fraction dose of radiation using the Xoft System at the time of lumpectomy.
ICAD: 10.31 (-0.08)
iCAD to Present at LD MICRO "Main Event" Micro-Cap Growth Conference on Tuesday, December 2, 2014
Business Wire - Wed Nov 26, 7:00AM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Company management will participate in the upcoming LD MICRO "Main Event" Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Ken Ferry, President and CEO of iCAD, Inc., will present a corporate overview on Tuesday, December 2, 2014 at 12:30 p.m. PST (3:30 p.m. EST).
ICAD: 10.31 (-0.08)
iCAD Showcases Advanced Mammography and Computed Tomography Colonography (CTC) CAD Solutions at Radiological Society of North America 2014 Annual Meeting
PR Newswire - Tue Nov 25, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will feature advanced computer-aided detection (CAD) solutions for the early detection of breast and colon cancers during the 100th Annual Meeting of the Radiological Society of North America (RSNA), in Chicago, Nov. 30 - Dec. 5. Symposia, posters, and workshops discuss the application of iCAD technologies and workflow solutions for enhanced cancer identification, breast density analysis, and tumor characterization. iCAD's 2D mammography, tomosynthesis, and Computed Tomography Colonography (CTC) CAD and workflow technologies will be featured at booth #4135 in Hall A.
ICAD: 10.31 (-0.08)
iCAD raises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:46AM CDT
ICAD: 10.31 (-0.08)
iCAD (ICAD) CEO Ken Ferry on Q3 2014 Results - Earnings Calls Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 9:45PM CDT
ICAD: 10.31 (-0.08)
iCAD, Inc. beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:21PM CDT
ICAD: 10.31 (-0.08)
iCAD Reports Third Quarter Financial Results
Business Wire - Tue Oct 28, 3:06PM CDT
--Increases Financial Guidance for 2014
ICAD: 10.31 (-0.08)
iCAD to Host Third Quarter 2014 Financial Results Conference Call on Tuesday, October 28, 2014
PR Newswire - Tue Oct 21, 7:30AM CDT
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the three and nine months ended September 30, 2014 following the close of the market on Tuesday, October 28, 2014.
ICAD: 10.31 (-0.08)
Icad Shares Up 36.0% Since SmarTrend's Buy Recommendation (ICAD)
Comtex SmarTrend(R) - Thu Sep 25, 9:11AM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 2 months, Icad has returned 35.98% as of today's recent price of $9.94.
ICAD: 10.31 (-0.08)
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into iCAD Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Thu Sep 18, 4:15PM CDT
Levi & Korsinsky, LLP is investigating iCAD Inc. (Nasdaq: ICAD) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
ICAD: 10.31 (-0.08)
Icad Has Returned 37.8% Since SmarTrend Recommendation (ICAD)
Comtex SmarTrend(R) - Wed Sep 17, 4:40PM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 2 months, Icad has returned 37.76% as of today's recent price of $10.07.
ICAD: 10.31 (-0.08)
iCAD to Present at the 5th Annual Craig-Hallum Alpha Select Conference
Business Wire - Wed Sep 17, 7:30AM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announces that Company management will participate in the 5th Annual Craig-Hallum Alpha Select Conference taking place on Thursday, September 18th at the Convene Conference Center in New York City. Ken Ferry, President and Chief Executive Officer of iCAD, will be presenting a corporate overview at 1:30 pm in the Murray Hill Room.
ICAD: 10.31 (-0.08)
iCAD to Showcase its Comprehensive Electronic Brachytherapy Solutions and Services at 56th Annual American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting
PR Newswire - Thu Sep 11, 7:00AM CDT
(Booth #1938) -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will debut the Company's latest technological advances and present updates on clinical data and patient outcomes using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® in the treatment of cancer during the upcoming American Society for Therapeutic Radiology and Oncology (ASTRO) meeting taking place September 14-17, 2014 at the Moscone Center in San Francisco. Throughout the meeting, iCAD will also showcase its expanded and comprehensive software and service offerings following the recent acquisitions of DermEbx and Radion, and will highlight innovations in technology with live product demonstrations of its Xoft System at Booth #1938.
ICAD: 10.31 (-0.08)
Icad Up 50.2% Since SmarTrend Uptrend Call (ICAD)
Comtex SmarTrend(R) - Wed Sep 10, 10:58AM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 2 months, Icad has returned 50.22% as of today's recent price of $10.98.
ICAD: 10.31 (-0.08)
iCAD Expands Partnership with Volpara Solutions to Offer Enhanced Breast Imaging Analytics for 2D Mammography and Tomosynthesis
PR Newswire - Thu Sep 04, 7:00AM CDT
iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that, in addition to Volpara®Density(TM) volumetric breast density assessment software, Volpara®Analytics(TM) and Volpara®Dose(TM) solutions are now available as part of iCAD's PowerLook Advanced Mammography Platform (AMP)®. With the addition of these quantitative breast imaging tools, radiologists will be able to evaluate the performance of all major digital mammography and tomosynthesis units and obtain patient-specific dose information to make informed treatment decisions in real time.
ICAD: 10.31 (-0.08)
Icad Has Returned 50.2% Since SmarTrend Recommendation (ICAD)
Comtex SmarTrend(R) - Wed Sep 03, 9:35AM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 2 months, Icad has returned 50.18% as of today's recent price of $10.98.
ICAD: 10.31 (-0.08)
Uptrend Call Working As Icad Stock Rises 42.7% (ICAD)
Comtex SmarTrend(R) - Wed Aug 27, 9:13AM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 1 month, Icad has returned 42.68% as of today's recent price of $10.43.
ICAD: 10.31 (-0.08)
Shares of ICAD Up 38.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 19, 4:48PM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 1 month, Icad has returned 38.29% as of today's recent price of $10.11.
ICAD: 10.31 (-0.08)
